Curis, Inc. (CRIS) P/E Ratio History
Deep ValueTrading at -0.7x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2003–2012
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Curis, Inc. (CRIS) trades at a price-to-earnings ratio of -0.7x, with a stock price of $0.42 and trailing twelve-month earnings per share of $-0.11.
The current P/E is 100% below its 5-year average of 284.4x. Over the past five years, CRIS's P/E has ranged from a low of 20.9x to a high of 635.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CRIS trades at a 103% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, CRIS trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CRIS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CRIS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CRIS P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 19.2 | - | +1747%Best | |
| $7B | 10.2 | - | +264% | |
| $2B | 6.8Lowest | 0.66Best | +817% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CRIS Historical P/E Data (2003–2012)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2012 Q3 | Sep 30 2012 | $414.00 | $2.10 | 197.1x | -31% |
| FY2012 Q2 | Jun 30 2012 | $540.00 | $0.85 | 635.3x | +123% |
| FY2003 Q3 | - | $439.00 | $21.00 | 20.9x | -93% |
Average P/E for displayed period: 284.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRIS — Frequently Asked Questions
Quick answers to the most common questions about buying CRIS stock.
What is CRIS's P/E ratio?
Curis, Inc. (CRIS) trailing twelve-month P/E ratio is -0.7x, based on TTM diluted EPS of $-0.11. The 5-year average P/E is 284.4x and the historical range spans 20.9x to 635.3x.
Is CRIS stock overvalued or undervalued?
CRIS trades at -0.7x P/E, below its 5-year average of 284.4x. At the 0th percentile of its historical range (20.9x–635.3x), the stock is priced at a discount to its own history.
Is CRIS stock expensive?
No, CRIS is not expensive on a historical basis. The current P/E of -0.7x is below the 5-year average of 284.4x and sits at the 0th percentile of its valuation range.
What is CRIS's historical P/E range?
Over the past 5 years, CRIS's P/E ratio has ranged from 20.9x to 635.3x, with a median of 197.1x and an average of 284.4x. The current P/E of -0.7x places the stock at the 0th percentile of this range. Full historical data spans 2003–2012.
How does CRIS's P/E compare to the S&P 500?
CRIS trades at -0.7x P/E versus the S&P 500 median of 24.4x. The 103% discount to the market suggests lower growth expectations or perceived higher risk.
How does CRIS's valuation compare to Healthcare peers?
Curis, Inc. P/E of -0.7x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CRIS's PEG ratio?
CRIS PEG ratio is N/A, based on a P/E of -0.7x and EPS growth of 91.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CRIS's earnings yield?
CRIS earnings yield is N/A, the inverse of its -0.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.